Arcos Dorados Holdings Inc. is a leading fast-food restaurant chain in Latin America and the Caribbean, primarily operating as a franchisee of McDonald's
The company specializes in serving a diverse menu that includes burgers, chicken, salads, and breakfast items, catering to local tastes and preferences across various countries. With a strong commitment to quality service and community engagement, Arcos Dorados seeks to provide a convenient and enjoyable dining experience while focusing on sustainability and corporate social responsibility initiatives in the regions it serves.
What a brutal six months it’s been for Arcos Dorados. The stock has dropped 23.8% and now trades at $7.24, rattling many shareholders. This may have investors wondering how to approach the situation.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the traditional fast food stocks, including Arcos Dorados (NYSEARCO) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Portillo's (NASDAQPTLO) and the best and worst performers in the traditional fast food industry.
Arcos Dorados renews its franchise agreement with McDonald's for 20 years, boosting stock and signaling continued market strength in Latin America and the Caribbean.
Let’s dig into the relative performance of Papa John's (NASDAQPZZA) and its peers as we unravel the now-completed Q3 traditional fast food earnings season.
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the traditional fast food industry, including Dutch Bros (NYSEBROS) and its peers.
Fast-food chain Arcos Dorados (NYSEARCO) met Wall Street’s revenue expectations in Q3 CY2024, but sales were flat year on year at $1.13 billion. Its GAAP profit of $0.17 per share was 5.3% above analysts’ consensus estimates.
Arcos Dorados (NYSEARCO) becomes a regional sponsor of Formula One in Latin America, aiming to leverage its Three-D's strategy and drive-through segment success.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQSGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
